Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence. Article Links: Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. (Heart rhythm) Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. (Heart rhythm) Full episode page: https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/ Featured Articles Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242357 Summary: The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract. Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242356 Summary: This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract. Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242355 Summary: This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists